Santarus Inc

Santarus — Investor Day (January 2011)

108 slides from Santarus's investor day presentation, Jan 20, 2011

  1. Slide 1: Analyst Day and Investor Briefing

    NasdaqGS: SNTS Analyst Day and Investor Briefing January 19, 2011

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its

  3. Slide 3: Agenda

    Agenda Welcome Martha L. Hough, Vice President, Finance and Investor Relations, Santarus, Inc. Strategic Overview and 2011 Financial Outlook Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc. Cycloset(r) - Clinical/Medical Background Dr. J. Michael Gaziano, Chief, Divisi

  4. Slide 4: Agenda - Continued

    Agenda - Continued Ulcerative Colitis - Treatment Perspective Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology, University of California, San Diego Rhucin(r) and Hereditary Angioedema (HAE) Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Alle

  5. Slide 5: Santarus Business Strategy

    Santarus Business Strategy Develop and commercialize proprietary pharmaceutical products Address unmet medical needs of patients treated by physician specialists Balance product portfolio and investments in R&D and SG&A to achieve meaningful, sustainable growth in revenues and profits Business decis

  6. Slide 6: Attractive Mix of Commercial & Development Opportunities

    Santarus Offers Attractive Mix of Commercial & Development Opportunities Development Opportunities Development Opportunities *Zegerid(r) is a non-promoted prescription product that continues to generate revenue. In addition, Zegerid OTC(r) is promoted by Merck Consumer Care. GlaxoSmithKline and Norg

  7. Slide 7: Product Focus - Create Competitive Advantage

    Product Focus - Create Competitive Advantage Product Focus - Create Competitive Advantage Unmet Medical Needs Multiple Indications Multiple Formulations Patents and/or Technology Product Differentiation Balanced Portfolio Pricing Flexibility January 19, 2011 7

  8. Slide 8: Specialty Focus - Leverage Commercial Investment

    Specialty Focus - Leverage Commercial Investment Sales Reps Physician Specialist Today Near Term Long Term Products & Product Candidates 110 Endocrinologists X Glumetza(r)Cycloset(r) +80 Gastroenterologists X Ultesa(tm)Rifamycin SV MMX(r)SAN-300 +25 Allergists/Immunologists X Rhucin(r)SAN-300 +30 Rh

  9. Slide 9: Financial Focus - Increase Shareholder Value

    Financial Focus - Increase Shareholder Value Sales per Rep Revenue SG&A as % Revenue R&D as % Revenue Profits & Cash Flow January 19, 2011 9

  10. Slide 10: Historical Financial Performance 2005 - 2009

    Historical Financial Performance 2005 - 2009 Total Revenue $27 $49 $94 $130 $172 Net Income (Loss) 2004 2005 2006 2007 2008 2009 Net Loss -83 -65 -56 -44 -18.5 32.1 2005 2006 2007 2009 2008 - -$65 - -$56 - -$44 - -$19 $32 ($ Millions) January 19, 2011 10

  11. Slide 11: Financial Results through September 2010

    Three Months Ended Sept 30, *First quarter of generic competition for Zegerid(r) **Includes $7.3 million in restructuring costs and $15 million upfront for Rhucin agreement Cash, cash equivalents & short-term investments: $65.1 million at September 30, 2010 Financial Results through September 2010 (

  12. Slide 12: 2011 Financial Outlook

    2011 Financial Outlook Expect top-line revenue growth to be positively impacted by resupply of Glumetza(r) 500 mg and launch of Cycloset(r) Realize benefit from full year impact of 3Q 2010 restructuring, which significantly reduced commercial infrastructure Estimate revenues of at least $110 million

  13. Slide 13: Near Term Value Drivers for Santarus

    Near Term Value Drivers for Santarus Glumetza(r) return to revenue growth Cycloset(r) educate endocrinologists and establish sales momentum Rhucin(r) BLA acceptance for FDA review expected in February 2011 Initiation of Rhucin Phase III study sites in HAE in January 2011 Estimate 12 to 18 months to

  14. Slide 14: J. Michael Gaziano, MD, MPH

    J. Michael Gaziano, MD, MPH Professor of Medicine, Harvard Medical School Chief, Division of Aging, Brigham and Women's Hospital

  15. Slide 15: Accountant with Early Diabetes

    Accountant with Early Diabetes 59-year-old man No history of CVD Father died at age 45 of MI Nonsmoker BP: 144/89 mm Hg (treated) BMI 29 Lipid parameters Total cholesterol: 243 mg/dL LDL-C: 172 mg/dL HDL-C: 36 mg/dL Triglycerides: 168 mg/dL Fasting Blood Sugar 138 January 19, 2011 15

  16. Slide 16: Classification of Interventions

    Classification of Interventions Class I Basic and observational research support causal association Intervention studies document benefit of modification Cost- and risk-benefit data available Class II Basic and observational research support causal association Intervention data are limited No cost ^

  17. Slide 17: Class I and II Risk Factors/Interventions

    Class I Class II Smoking Dyslipidemia Hypertension Prophylactic Meds: Aspirin Diabetes / Pre-Diabetes Physical inactivity Obesity Diet / Alcohol intake Gaziano, Ridker, Libby; in Heart Disease, Braunwald. Class I and II Risk Factors/Interventions January 19, 2011 17

  18. Slide 18: Antidiabetic Therapies Lack Evidence of Efficacy in Reducing CVD Events

    Antidiabetic Therapies Lack Evidence of Efficacy in Reducing CVD Events Current therapies were initially approved on the basis of glucose and HbA1C endpoints. Tight glucose control may delay progression of retinopathy, renal disease, and neuropathy, but there are limited data in the prevention of ma

  19. Slide 19: Previous Trials of Tight vs. Conventional Glycemic Control

    Study CVD MortalityRR (95% CI) Nonfatal MIRR (95% CI) Fatal and Nonfatal StrokeRR (95% CI) UKPDS, 1998 0.81 (0.65 - 1.02) 1.12 (0.83 - 1.52) 1.12 (0.83 - 1.52) VADT, 2009 1.32 (0.83 - 2.11) 0.78 (0.55 - 1.11) 0.78 (0.48 - 1.27) ADVANCE, 2008 0.88 (0.74 - 1.03) 0.98 (0.79 - 1.22) 0.97 (0.81 - 1.15) A

  20. Slide 20: Insulin-resistance State

    Highly conserved trait over 400 million years of vertebrate evolution. Confers a major survival advantage. Seasonally induced; centrally controlled through circadian neuroendocrine systems. Deleterious when it becomes over-expressed and permanent. Inherent plasticity in these central systems permits

  21. Slide 21: Annual Cycle of Body Fat Levels in White-throated Sparrows

    Body fat (%) dry weight May August Annual Cycle of Body Fat Levels in White-throated Sparrows January 19, 2011 21

  22. Slide 22: Influences on Peripheral Metabolism

    Daylight, diet, activity Influences on Peripheral Metabolism Circadian "Clock" Governs Other Hypothalamic Metabolic Control Centers January 19, 2011 22

  23. Slide 23: Seasonal Variation Among Hunter-gatherers and Western Populations

    Seasonal Variation Among Hunter-gatherers and Western Populations % body fat Years % body fat Years January 19, 2011 23 Hunter-gatherers Western Populations

  24. Slide 24: Cycloset (bromocriptine mesylate)

    Scraton R. BMC Endocrine Disorders 2007:7:1-3 Cycloset(r) (bromocriptine mesylate) Cycloset is the first and only centrally-acting dopamine agonist for the treatment of adults with type 2 diabetes that reduces insulin resistance resulting in a decrease in hepatic glucose output and an increase in ti

  25. Slide 25: Cycloset: Proposed Mechanism of Action

    Cycloset(r): Proposed Mechanism of Action Morning administration (within 2 hours of waking) of CYCLOSET Corrects Restoration of morning peak in dopaminergic activity (via D2 receptor-mediated activity) Decreased postprandial glucose levels Reduction in insulin resistance Day-long reduction in plasma

  26. Slide 26: Cycloset Efficacy and Safety

    Cycloset(r) Efficacy and Safety* *Please see www.Cycloset.com for full prescribing and safety information

  27. Slide 27: Summary of Cycloset Phase III Efficacy Data

    Summary of Cycloset(r) Phase III Efficacy Data Four phase III studies that evaluated safety and efficacy1,2 One 24-week monotherapy trial (n = 159) Cycloset plus diet and exercise compared to placebo Two 24-week add-on to sulfonylurea trials (n = 494) Cycloset plus SU compared to placebo plus SU One

  28. Slide 28: Effect of Cycloset Monotherapy on Diurnal Plasma Glucose Levels

    † ANOVA analysis of treatment and hour indicate a significant treatment effect over the entire diurnal (7 am to 7 pm) period (p<0.02) *Significantly different from control (p<0.05) Decrement in A1c (-0.6%, p=0.018) at 24 weeks - -40 0 40 - -31 - -35 - -39* - -31 - -49 - -47* - -16 - -23 - -32* Place

  29. Slide 29: Effect of Cycloset on Plasma Triglyceride and FFA Levels

    Scranton and Cincotta. Expert Opin Pharmacother 2010;11:269-7 29% P<0.01 19% P<0.02 - -200 - -100 0 100 200 Plasma FFA- Change From Baseline (meg/L) - -150 - -195 - -180 - -114 - -169 - -183 - -136 - -166 - -109 Placebo CYCLOSET Fasting FFA = 850 ?g/L ?TG vs Placebo - -80 - -40 0 40 80 - -91 - -111

  30. Slide 30: Cycloset Safety Trial: 24 Week Evaluation of A1c Reduction

    Data on file, Santarus, Inc Scranton et al, Diabetologia 2008; 51 (Suppl. 1): S372-373. Poster, EASD 2008. Rome, Italy Cincotta et al, Diabetologia 2008; 51 (Suppl. 1): S22. Poster, EASD 2008. Rome, Italy 0.6% to 0.9% HbA1c reductions vs. placebo when Cycloset added to other oral antidiabetics (OAD)

  31. Slide 31: Cycloset: Summary of Efficacy

    Cycloset (r): Summary of Efficacy Following once-daily, early morning administration of Cycloset: Cycloset controlled glucose throughout the day, reducing postprandial glucose without increasing insulin levels Cycloset reduced HbA1c by 0.6%-0.9% vs. placebo when added to other oral antidiabetics Cyc

  32. Slide 32: Cycloset Safety Trial

    Cycloset(r) Safety Trial Phase III Clinical Trial Where Overall Safety and CV Safety Were the Primary Objectives Diabetes Care July 2010 January 19, 2011 32

  33. Slide 33: Cycloset Safety Trial Design

    Cycloset(r) Safety Trial 52 Week, 74 Center RCT, Assessed the Safety (All Cause Serious Adverse Events and CVD Safety) and Efficacy of Cycloset in a Broad Patient Population of Adults with Type 2 Diabetes Mellitus (n = 3070) Real World Patient Population - Broad Inclusion Criteria Age 30 - 80 years

  34. Slide 34: KM Curve - Composite CVD Endpoint

    *MI, Stroke, hospitalization unstable angina, hospitalization CHF, or coronary revasc. KM Curve: the separation in favor of Cycloset begins 3 months and persists through the end of the study HR 0.58 (95% CI 0.35-0.96) RRR=42% KM Curve - Cycloset(r) Safety Trial Cumulative Percent Composite CVD Endpo

  35. Slide 35: KM Curve - MACE Endpoint

    ADA in abstract 2008 HR 0.45 (95% CI 0.2-0.99) KM Curve: the separation in favor of Cycloset begins 3 months and persists through the end of the study RRR= 55% KM Curve - Cycloset(r) Safety Trial Cumulative Percent MACE Endpoint January 19, 2011 35

  36. Slide 36: Summary

    Summary First centrally acting dopamine agonist for the treatment of type 2 diabetes in adults Unique formulation with no therapeutic equivalent Decreases post-meal hyperglycemia without increasing plasma insulin release Reduces HbA1c between 0.4 - 0.9% alone or in combination with anti-diabetes med

  37. Slide 37: Accountant with Early Diabetes

    Accountant with Early Diabetes January 19, 2011 37 59-year-old man No history of CVD Father died at age 45 of MI Nonsmoker BP: 144/89 mm Hg (treated) BMI 29 Lipid parameters Total cholesterol: 243 mg/dL LDL-C: 172 mg/dL HDL-C: 36 mg/dL Triglycerides: 168 mg/dL Fasting Blood Sugar 138

  38. Slide 38: Overview of Budesonide MMX (Ultesa) Phase III Results

    Overview of Budesonide MMX(r) (Ultesa(tm)) Phase III results: US and EU trials Simon Travis, DPhil FRCP Translational Gastroenterology Unit Oxford, UK

  39. Slide 39: Ulcerative Colitis

    Diffuse, mucosal inflammation Characterised by bloody diarrhoea (96%), Distribution: proctitis (40%), distal (40%), extensive (20%) Activity: Remission (50%), mild or moderate (45%/yr), severe (5%/year) EU: About 500,000 cases of UC (120 cases/100000 and 456m population in EU25) Costs €1800 per pati

  40. Slide 40: Crohn's Disease

    Crohn's Disease Patchy, transmural inflammation Characterized by pain, non-bloody diarrhoea and weight loss Distribution: terminal ileal (30%), colonic (30%), ileocolic (30%), other Variable pattern: inflammatory, fistulating, or stricturing Differs from UC Only 30% have isolated colonic disease Str

  41. Slide 41: Management of Mild to Moderate UC

    Oral 5-ASA Mesalazine 1.5-4.8 g/d Balsalazide 6.75 g/d Sulfasalazine 4-6 g/d Extensive (pancolitis) Rectal 5-ASA Induction 5-ASA, AZA/6-MP, infliximab Corticosteroids ECCO Consensus on UC: management J Crohn's & Colitis 2008;2:24-56. Infliximab Maint +- 1st-Line 2nd-Line 3rd-Line Management of Mild

  42. Slide 42: Recognition of Need for Better Therapy

    Recognition of Need for Better Therapy January 19, 2011 42

  43. Slide 43: Budesonide and the Multi Matrix System (MMX)

    Inert matrix Hydrophilic matrix Budesonide and the Multi Matrix System (MMX(r)) Gastroprotectant layer LV hydrophilic - amphipatic polymer matrix HV hydrophilic polym. matrix Inert matrix material Drug (+ excipient) January 19, 2011 43

  44. Slide 44: Budesonide MMX 9mg

    Budesonide MMX(r) 9mg Budesonide Highly potent corticosteroid Low systemic bioavailability Established value as topical therapy in UC and targeted delivery for CD Budesonide MMX (Ultesa(tm)) Gastro-resistant MMX delivery Two large phase III trials in UC NCT00679380 MMX 9mg vs 6mg vs Entocort (r) vs

  45. Slide 45: Ultesa Phase III Study Design

    Ultesa(tm) Phase 3 Study Design US & EU Studies US & EU Studies US & EU Studies January 19, 2011 45

  46. Slide 46: Ultesa Phase III Headline Results

    Ultesa(tm) Phase 3 Study Data Headline Results: US & EU Studies Ultesa 9 mg met statistical significance on the primary endpoint for both US & EU studies: p-value 0.0143 (US); 0.0047 (EU) The frequency of treatment-related adverse events and serious adverse events including potential glucocorticoid-

  47. Slide 47: Primary Endpoint Efficacy Analysis (US & EU Studies)

    (CHART) (CHART) U.S. Phase III Clinical Study (N= 489) E.U. Phase III Clinical Study (N= 410) 7.4% 13.2% 12.1% 4.5% 17.4%* 8.3% 12.6%** Placebo n=121 Placebo N=89 Ultesa 9mg n=123 Ultesa 9mg N=109 Ultesa 6mg n=121 Ultesa 6mg N=109 Asacol(r) n=124 Entocort(r) EC n=103 * Statistically significant vs.

  48. Slide 48: Primary Endpoint Efficacy Analysis Tables

    US Study CB-01-02/01 PlaceboN= 121n (%) MMX 9 mgN= 123n (%) MMX 6 mgN= 121n (%) AsacolN= 124n (%) Patients in Remission 9 (7.4) 22 (17.9) 16 (13.2) 15 (12.1) p-value 0.0143 0.1393 0.2200 EU Study CB-01-02/02 PlaceboN= 89n (%) MMX 9 mgN= 109n (%) MMX 6 mgN= 109n (%) EntocortN= 103n (%) Patients in Re

  49. Slide 49: Impact of Different Definitions on Outcomes

    Impact of Different Definitions on Outcomes Differences in defining remission 'within' a clinical trial ASCEND I and II studies: retrospective analysis1 EGF study: in-study analysis2 Katz et al. Gastroenterol 2006;130(Suppl 2):A-482. Abstract. T1136 Sinha et al. N Eng J Med 2003;349:350-357 Study AS

  50. Slide 50: Contrasting Remission Rates Lialda and Ultesa

    Contrasting Remission Rates Lialda(r) and Ultesa(tm) Protocol Design Differences Lialda(r) and Ultesa(tm) Protocol Design Differences Lialda(r) and Ultesa(tm) Protocol Design Differences January 19, 2011 50

  51. Slide 51: Ultesa Phase III Safety Assessment

    Treatment related AE data from U.S. and E.U. studies Ultesa(tm) Phase 3 Safety Assessment Adverse Event Profile January 19, 2011 51

  52. Slide 52: Ultesa Phase III Safety Assessment: Plasma Cortisol

    Ultesa(tm) Phase 3 Safety Assessment Plasma Cortisol (Pooled Data) Symbols indicate the mean plasma Cortisol level for each visit for each treatment. Error bars indicate the 25th and 75th percentiles. Treatments are offset for ease of readability. January 19, 2011 52

  53. Slide 53: Conclusions

    Conclusions Budesonide MMX(r) (Ultesa(tm)) was shown to induce remission in active ulcerative colitis in two Phase III clinical studies Two Phase III studies: US and EU, 1020 patients enrolled Robust selection: histological disease activity at baseline (quality control) Real remission: no bleeding,

  54. Slide 54: January 19, 2011 54

    January 19, 2011 54

  55. Slide 55: Perspective on Treatment of Ulcerative Colitis in the U.S.

    Perspective on Treatment of Ulcerative Colitis in the U.S. William J. Sandborn, M.D. University of California San Diego La Jolla, California

  56. Slide 56: Estimates of IBD Prevalence - North America

    Estimates of IBD Prevalence - North America Estimates of IBD Prevalence - North America Ingle SB, et al. Gastroenterology 2007;132(Suppl):A19. Bernstein CN, et al. Am J Gastroenterol 2006;101:1559. Herrinton LJ, et al. Inflamm Bowel Dis 2007;13:451. Kappelman MD, et al. Clin Gastroenterol Hepatol 20

  57. Slide 57: Management of UC

    Oral 5-ASAs Mesalamine 1.5-4.8 g/d Balsalazide 6.75 g/d Sulfasalazine 4-6 g/d Distal (left-sided, proctitis) Rectal 5-ASA or Rectal steroid Induction 5-ASA, AZA/6-MP, infliximab Oral steroid AZA/6-MP Kornbluth A, Sachar D. Am J Gastroenterol. 2004;99:1371. Baumgart DC, Sandborn WJ. Lancet. 2007;369:

  58. Slide 58: 5-ASA Formulations

    Delayed-Release: pH-dependent soluble polymer- coated tablets (release at pH ^7) Delayed Release: Gastro-resistant polymer film- coated tablets (release at pH ^7) Azo-Bonded Agents1 Controlled Release: Ethylcellulose-coated microgranules (time-dependent release) Lialda? Inert carrier Balsalazide Ols

  59. Slide 59: 5-Aminosalicylate (5-ASA, Mesalamine) for UC

    5-Aminosalicylate (5-ASA, Mesalamine) for UC Effective for induction and maintenance of response and remission in mild to moderate UC Advances More formulations No clear differences in efficacy Higher unit doses Some can be given once daily No clear dose response above 2.4 g/day January 19, 2011 59

  60. Slide 60: Delayed Release Oral Mesalamine: Mild-to-Moderate Active UC

    Significant Improvement Placebo 23 Mesalamine 1.6 g 43 Mesalamine 2.4 g 49 Remission Placebo 5 Mesalamine 1.6 g 14 Mesalamine 2.4 g 14 *Mucosal healing not assessed †Defined as "in remission" (complete resolution of all symptoms with all assessment scores = 0), OR "improved" (reduction in PGA score

  61. Slide 61: Remission at Week 8 With Delayed-Release Mesalamine

    Kamm1 -2.4 g/day in divided doses, 4.8 g/day as a single daily dose Lichtenstein2 -2.4 and 4.8 g/day as a single daily dose 1. Kamm MA. Gastroenterology. 2007;132:66. 2. Lichtenstein GR. Clin Gastroenterol Hepatol. 2007;5:95. Patients in Clinical and Endoscopic Remission at Week 8 (%) 0 10 20 30 40

  62. Slide 62: Delayed Release Oral Mesalamine: Maintenance of Endoscopic Remission

    Treatment Success Placebo 48 Mesalamine 0.8 g 63 Mesalamine 1.6 g 70 †Defined as "maintenance of endoscopic remission at 6 months" (score of 0 out of 3 on sigmoidoscopic scale) ‡P=.05 §P=.005 Hanauer SB et al. Ann Intern Med. 1996;124:204. ‡ § † Percent of patients Delayed Release Oral Mesalamine: U

  63. Slide 63: Steroids for UC

    Steroids for UC Effective for induction of response and remission in moderate to severe UC Advances No long term efficacy Increased risk of infection and mortality January 19, 2011 63

  64. Slide 64: Oral Cortisone: Clinical Response and Remission at 6 Weeks

    Clinical response Clinical remission Placebo (n=101) 41 16 Cortisone (n=109) 69 41 *Clinical remission defined as 1 or 2 stools/day without blood †Clinical response defined as improved or clinical remission Truelove SC. Br Med J. 1954;4884:375. P<0.001 P<0.001 * † Oral Cortisone: Mild-to-Severe Acti

  65. Slide 65: Oral Cortisone: Mucosal Healing at 6 Weeks

    Mucosal healing Placebo (n=57) 11 Cortisone 100 mg/d (n=63) 30 *Defined as normal or near normal (slight hyperemia or granularity) mucosa Truelove SC. Br Med J. 1954;4884:375. P=.02 * Oral Cortisone: Mild-to-Severe Active Ulcerative Colitis: Mucosal Healing at 6 Weeks January 19, 2011 65

  66. Slide 66: Mortality Associated with Current and Recent Corticosteroid Use

    Lewis JD, et al. Am J Gastroenterol. 2008;103:1428-1435. Hazard Ratio 95% CI: (2.26-3.5) 95% CI: (1.65-3.75) Recent Use of Corticosteroids Current Use of Corticosteroids Mortality Associated with Current and Recent Corticosteroid Use - Adjusted HR (95% CI) January 19, 2011 66

  67. Slide 67: Azathioprine for UC

    Azathioprine for UC Widely used for maintenance of remission and steroid sparing in moderate to severe UC Advances Meta-analysis showed equivocal/ modest efficacy 4-fold increase in risk of non-Hodgkins lymphoma (majority linked to EBV) January 19, 2011 67

  68. Slide 68: Efficacy of AZA for Treatment Success in UC: Meta-Analysis

    Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis Leung Y, et al. Dig Dis Sci. 2008;53:1455-1461. Pooled RR Estimate Across Five Trials January 19, 2011 68

  69. Slide 69: Toxicity of Azathioprine and 6-Mercaptopurine in IBD

    Toxicity of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease Opportunistic Infections Lymphoma Meta-analysis of 6 studies showed that AZA/6MP treatment is associated with 4-fold increase (SIR = 4.2 [95% CI = 2.1 - 7.5]) in risk of EBV-positive lymphoma Bone marrow depression (leukopen

  70. Slide 70: Anti-TNF Antibody (Infliximab) for UC

    Anti-Tumor Necrosis Factor Antibody (Infliximab) for UC Induces and maintains clinical response and remission, mucosal healing, and steroid sparing January 19, 2011 70

  71. Slide 71: Infliximab Induction and Maintenance Therapy: Clinical Remission

    †P?.003 vs placebo ‡P<.001 vs placebo 8 Weeks 30 Weeks Placebo 6 11 IFX 5 mg/kg 34 26 IFX 10 mg/kg 28 36 8 Weeks 30 Weeks 54 Weeks Placebo 15 16 17 IFX 5 mg/kg 39 34 35 IFX 10 mg/kg 32 37 34 ‡ ‡ ‡ † † ‡ ‡ ‡ ACT 1 ACT 2 ‡ ‡ Rutgeerts P. N Engl J Med. 2005;353:2462. Infliximab Induction and Maintenanc

  72. Slide 72: Anti-TNF Antibody Toxicity

    Anti-TNF Antibody Toxicity Non-Hodgkin's lymphoma Hepatosplenic T cell lymphoma in children on infliximab or adalimumab + azathioprine ? Skin cancer ? Solid tumors Serious infections Opportunistic Infections (including granulomatous infections such as tuberculosis and histoplasmosis) January 19, 201

  73. Slide 73: Surgical Options in Ulcerative Colitis

    Conventional ileostomy (Brooke) Continent ileostomy (Kock pouch) Ileal pouch-anal anastomosis Ileorectal anastomosis CP1288478-73 Surgical Options in Ulcerative Colitis January 19, 2011 73

  74. Slide 74: Risks Of Surgical Therapy For Ulcerative Colitis

    Risks Of Surgical Therapy For Ulcerative Colitis Increased stool frequency (median 6/day, 1/night) Fecal incontinence Pouchitis (50%) Cuffitis (? 20%) Reoperation for SBO due to adhesions Reoperation for ventral hernia Female infertility (50%) Permanent stoma (30-40%) Pouch excision (10%) Mortality

  75. Slide 75: Potential Role of Budesonide MMX (Ultesa) in the Therapy of UC

    Potential Role of Budesonide MMX(r) (Ultesa(tm)) in the Therapy of UC Primary induction therapy Induction therapy in patients failing mesalamine Adjunctive therapy in patients receiving azathioprine, 6- mercaptopurine or infliximab Maintenance therapy in patients who received induction therapy with

  76. Slide 76: Conclusions

    Conclusions Ulcerative colitis is a chronic condition with high morbidity Many patients treated with mesalamine do not achieve remission Treatment with conventional steroids, azathioprine and 6-mercaptopurine, and infliximab has important limitations Surgery is not an optimal solution, it leads to i

  77. Slide 77: Overview of HAE Treatment Options in the U.S.

    Overview of HAE Treatment Options in the U.S. Bruce L. Zuraw, M.D. Chief, Allergy & Immunology, UCSD

  78. Slide 78: Hereditary Angioedema (HAE)

    Hereditary Angioedema (HAE) January 19, 2011 78

  79. Slide 79: Epidemiology of HAE

    Epidemiology of HAE Estimated prevalence is difficult to ascertain Autosomal dominant inheritance Varying estimates of as high as 1 in 30,000 to as low as 1 in 80,000 Probably to 4000-10,000 affected individuals in United States No known ethnic or gender differences Average attack frequency in untre

  80. Slide 80: HAE Attack Characteristics

    HAE Attack Characteristics Angioedema, often quite severe Attacks prolonged Increasing intensity over first 24 hrs Resolving over next 2-4 days Pts may be ill 3-8 days or more per 2 weeks Extremity attacks Inability to go to work/school; Compartment syndromes Abdominal attacks Freq. need hospitaliza

  81. Slide 81: Location and Onset of HAE Symptoms

    Bork K, et al. Am J Med. 2006;119:267-274 Location and Onset of HAE Symptoms Retrospective study 221 HAE patients 5736 patient-years of observation 131,110 angioedema attacks January 19, 2011 81

  82. Slide 82: Treatment of Acute HAE Attacks Pre-2008

    Zuraw BL. N Engl J Med. 2008;359:1027-1036 Corticosteroids Antihistamines Epinephrine Treatment of Acute HAE Attacks Pre-2008 No reliable US FDA-approved therapy for acute attacks Extremity attacks No treatment given Often disabling Gastrointestinal attacks Often required hospitalization Risk of nar

  83. Slide 83: Bradykinin is the Mediator of AE in HAE

    Bradykinin is the Mediator of AE in HAE January 19, 2011 83

  84. Slide 84: Bradykinin Theory: Therapeutic Implications

    Zuraw BL. Immunol Allergy Clin North Am. 2006;26:691-708. Bradykinin Theory: Therapeutic Implications January 19, 2011 84

  85. Slide 85: pdC1INH (Berinert) for Acute HAE Attacks

    pdC1INH (Berinert(r)) for Acute HAE Attacks Craig, JACI 2009 p801 pdC1INH-p 20 U/kg bw (N=43) pdC1INH-p 10 U/kg bw (N=39) Placebo (N=42) P = 0.0025 vs placebo P = 0.2731 vs placebo January 19, 2011 85

  86. Slide 86: pdC1INH-nf (Cinryze) for Acute HAE Attacks

    Zuraw, NEJM 2010 p513 pdC1INH-nf (Cinryze(r)) for Acute HAE Attacks p = 0.019 vs placebo January 19, 2011 86

  87. Slide 87: Ecallantide (Kalbitor) for Acute HAE Attacks

    Riedl, Ann Allergy Asthma Immunol. 2010;105:430 Beginning of improvement Sustained improvement Plog rank = 0.09 Plog rank = 0.005 Plog rank = 0.04 Ecallantide (Kalbitor(r)) for Acute HAE Attacks Ecallantide Placebo January 19, 2011 87

  88. Slide 88: Icatibant (Firazyr) for Acute HAE Attacks

    Cicardi, NEJM 2010 p532 and Shire Press Release 12/1/10 FAST-1 (USA) FAST-2 (Europe) FAST-3 (World) p = 0.14 p < 0.001 p < 0.001 (N=44) (N=44) Icatibant (Firazyr(r)) for Acute HAE attacks January 19, 2011 88

  89. Slide 89: Recombinant Human C1INH

    Recombinant Human C1INH Recombinant human C1INH Rhucin(r) (Pharming/Santarus) hC1INH cDNA driven by mammary promoter rhC1INH from breast milk of transgenic rabbits Identical to plasma C1INH at protein level Post-translational (glycosylation) changes Inhibits proteases same as plasma C1INH January 19

  90. Slide 90: rhC1INH (Rhucin) Pharmacokinetics

    van Doorn, JACI, 116:876, 2005. rhC1INH (Rhucin(r)) Pharmacokinetics January 19, 2011 90

  91. Slide 91: rhC1INH (Rhucin) for Acute HAE Attacks

    d rhC1INH (Rhucin(r)) for Acute HAE Attacks Zuraw, JACI 126:821 2010 Time (hours) P = 0.013 P < 0.001 January 19, 2011 91

  92. Slide 92: Emerging Guidelines for HAE Treatment

    Emerging Guidelines for HAE Treatment Treatment should maximize patient health Abort attacks with early & effective treatment Minimize disruption of school, job, & sleep Avoid significant side effects Treatment should be individualized All patients should have effective therapy available to treat al

  93. Slide 93: Rhucin Versus Other HAE Treatments

    Rhucin(r) Versus Other HAE Treatments Rhucin advantages Drug supply is elastic and virtually inexhaustible Higher dosage normalizes C1-INH level and may be more effective in stopping attacks Lack of risk of infectious agents from human plasma Rhucin disadvantages Potential allergic reactions to rabb

  94. Slide 94: Summary

    Summary HAE is an uncommon but serious disease Key to minimizing morbidity and mortality is early recognition HAE results from C1INH mutations Bradykinin is the mediator of swelling Historical treatments variably effective but suboptimal New consensus emerging for improved treatment outcomes Emergin

  95. Slide 95: SAN-300 (Anti-VLA-1 Antibody)

    SAN-300 (Anti-VLA-1 Antibody) Mark C. Totoritis, M.D. Senior Vice President, Biologics Santarus, Inc. SAN-300 (Anti-VLA-1)

  96. Slide 96: SAN-300 (Anti-VLA-1) Overview

    SAN-300 (Anti-VLA-1) Overview Novel approach to autoimmune/inflammatory disease therapy The Target Integrin VLA-1 (?1?1 integrin) Major collagen receptor Expressed on activated T cells and monocytes VLA-1 mediates migration, retention and proliferation of these cells at sites of inflammation January

  97. Slide 97: VLA-1 Mediates Cell-Matrix Interactions

    VLA-1 Mediates Cell-Matrix Interactions January 19, 2011 97

  98. Slide 98: SAN-300 (Anti-VLA-1) Overview

    SAN-300 (Anti-VLA-1) Overview SAN-300 Humanized IgG1? antibody manufactured by recombinant expression in mammalian cells Binds ?1 subunit of VLA-1 with high affinity and inhibits adhesion to matrix molecules at low antibody concentration Non-depleting Existing drug supply adequate for early phase cl

  99. Slide 99: Anti-VLA-1 Preclinical Efficacy

    Anti-VLA-1 Preclinical Efficacy Strong efficacy in multiple preclinical models Rheumatoid arthritis Inflammatory bowel disease Psoriasis Corneal transplant Kidney disease (nephritis) Asthma Others January 19, 2011 99

  100. Slide 100: Anti-VLA-1 Reduces Cellular Infiltrate And Joint Erosion

    Normal Arthritic - IgG Control Arthritic - a1 Treated H&E Toluidine blue Anti-VLA-1 Reduces Cellular Infiltrate And Joint Erosion de Fougerolles et al. J Clin Invest 2000;105:721-29 January 19, 2011 100

  101. Slide 101: Anti-VLA-1 Inhibits Inflammation In DSS Colitis Model

    Krieglstein et al. J.Clin Invest 2002;110:1773-82 Anti-VLA-1 Inhibits Inflammation In DSS Colitis Model January 19, 2011 101

  102. Slide 102: Anti-VLA-1 Inhibits Inflammation In Psoriasis Model

    Anti-VLA-1 Inhibits Inflammation In Psoriasis Model In Psoriasis Model In Psoriasis Model Conrad et al. Nat Med 2007;13:836-42 January 19, 2011 102

  103. Slide 103: VLA-1+ T cells Correlate With Disease State in Human RA

    Ben-Horin et al. J Clin Immunol 2007;27:580-88 VLA-1+ T cells Correlate With Disease State in Human RA January 19, 2011 103

  104. Slide 104: Rheumatoid Arthritis

    Rheumatoid Arthritis Rheumatoid Arthritis January 19, 2011 104

  105. Slide 105: SAN-300 Initial Indication

    SAN-300 Initial Indication Initial indication: Rheumatoid arthritis Strong technical rationale Efficacy in multiple arthritis models - both prophylactic and therapeutic protocols High unmet medical need ?50% inadequate response to TNF inhibitors Clear development and regulatory path FDA guidance and

  106. Slide 106: SAN-300 Proposed Phase I Study Design

    SAN-300 Proposed Phase I Study Design Randomized, placebo-controlled, blinded, single-center, single-dose, dose-escalation study Objectives Primary: to evaluate safety and tolerability of single doses of anti-VLA-1Secondary: to characterize the PK and PD of single doses of anti-VLA-1 Sample Size &Tr

  107. Slide 107: Attractive Mix of Commercial & Development Opportunities

    Santarus Offers Attractive Mix of Commercial & Development Opportunities Development Opportunities Development Opportunities *Zegerid(r) is a non-promoted prescription product that continues to generate revenue. In addition, Zegerid OTC(r) is promoted by Merck Consumer Care. GlaxoSmithKline and Norg

  108. Slide 108: Question & Answer Session

    Question & Answer Session

Santarus — Investor Day (January 2011) on 6ix